The University of Kansas Cancer Center requests CCSG developmental funds to support pilot research projects, develop additional shared resources to strengthen research initiatives, support new faculty recruits and promote basic, translational and clinical science research activities. Funding pilot projects, developing shared resources, recruiting new faculty and supporting staff investigators will collectively enhance the ability of KUCC to serve the catchment area and mitigate the impact of cancer in the region. KUCC believes that these activities will enable the Cancer Center to provide the optimal environment to focus the power of precision medicine, basic science inquiry, drug discovery and development, and behavioral interventions to decrease cancer incidence, morbidity, and mortality. Furthermore, these activities will promote a cancer center culture whose highest priority is to leverage the collective state-of-the-art basic, clinical, translational and population research programs to understand cancer at a fundamental level and catalyze a comprehensive, multidisciplinary approach to defeating cancer. KUCC has demonstrated a successful track record in its investment of CCSG developmental funds and other KUCC-directed funding mechanisms and will continue to grow a strong return on investment from these funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-07
Application #
9528480
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Campos, Camila D M; Gamage, Sachindra S T; Jackson, Joshua M et al. (2018) Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18:3459-3470

Showing the most recent 10 out of 177 publications